Navigation Links
Generation of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus - Use of SPYMEG as a novel human lymphocyte fusion partner
Date:1/26/2010

NAGOYA, Japan, Jan. 26 /PRNewswire/ -- Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.

Professor Kazuyoshi Ikuta, Ph. D., at the Department of Virology, Research Institute for Microbial Diseases, Osaka University, has confirmed through in vitro experiments that the fully generated human antibodies can neutralize H3N2 influenza virus strains. Professor Ikuta is now evaluating the preventative and therapeutic effects in an infected mouse model. After completing in vivo experiments in infected animal models with the neutralizing antibodies, MBL plans to commence a collaborative clinical development program with a pharmaceutical company. These neutralizing human IgG antibodies against the influenza virus are expected to be effective in severe infections. In combination with anti-viral drugs these antibodies will have greater success than anti-viral drugs alone.

The therapeutic antibodies were generated by using a special cell line, called SPYMEG. This novel cell line is a human lymphocyte fusion partner, it was co-developed by associate professor Naomasa Yamamoto, Ph. D., of Ohu University and MBL. SPYMEG is the cell line established by the cell fusion of MEG-01 with a murine myeloma cell line. Hybridoma cells of human origin are known to be prone to chromosome deletions. The SPYMEG cell line overcomes that problem, resulting in a higher reliability of cell fusion. Utilization of SPYMEG is a simpler and easier way to generate therapeutic monoclonal antibodies than chimerization, or humanization of mouse monoclonal antibodies generated from immunized mice.

At present, MBL is conducting collaborative research to generate neutralizing monoclonal antibodies against swine-origin influenza A (H1N1). MBL is preparing to collaborate with more institutions regarding other infectious viruses.

The fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza viruses were generated by the utilization of SPYMEG. The antibodies, originated from the blood of a convalescent volunteer recovering from influenza infection or vaccination, are expected to be effective and very safe.

Additionally, the simple principle and wide range of applications of this method may lead to the generation of therapeutic and prophylactic drugs to various infections such as avian influenza A (H5N1).

About MBL

MBL was first established as a Japanese antibody manufacturer in 1969. Since then, the company has been involved in the research, development, manufacture and sale of diagnostic and research reagents.

In the research reagent sector, MBL has been engaged in the worldwide sales of more than 8,000 antibodies that are developed in-house or marketed by foreign and domestic alliance partners. MBL also provides the contract manufacturing of custom-made monoclonal and polyclonal antibodies. MBL has also extended its offering to provide identification kits for mRNA and contract analysis of carbohydrate structure.

In the diagnostic reagent sector, MBL has developed in vitro diagnostic reagents for autoimmune diseases, cancers and aberrant metabolite disorders. As a leader in autoimmune disease diagnostics, MBL's diagnostic products have aided detection of diseases, especially those with poor therapeutic options. MBL also provides an advanced cytopreparation system for the sampling and diagnosis of cervical cancer.

MBL is proud to be an antibody manufacturer with commitment to drug discovery focusing on therapeutic monoclonal antibodies.

About MBL International

MBL International, a subsidiary of MBL, is a leading biotechnology company focused on research, development, production and distribution of research reagents for the life science marketplace worldwide.

MBL International introduces a broad range of innovative antibodies and antibody-related products in the areas of immunology, cancer, autophagy, apoptosis, allergy, fluorescence and other research.  Our products include fluorescent protein vectors, kinase assay ELISA kits, monoclonal antibodies, recombinant proteins and the industry's largest selection of G-Protein Coupled Receptor antibodies.  MBL International also manufactures and distributes diagnostic ELISA and IF kits in the areas of autoimmune disease, virology and infectious diseases.

In 2008, MBL International increased the company's offering of diagnostic products that are used to test for and diagnose severe skin diseases, viral infections and many additional autoimmune diseases. MBL International is your immune system research provider.

SOURCE MBL International Corporation

RELATED LINKS
http://www.mblintl.com

'/>"/>

SOURCE MBL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix
2. Indiana Industry, University and Community Leaders Capitalize on Next Generation of States Life Sciences Growth
3. DONG Energy and Inbicon Inaugurate One of the Worlds Largest Demo Plants for 2nd Generation Biofuel
4. DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits
5. UD wins $4.4 million to develop next-generation magnets
6. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
7. Parameter Generation and Control Launches New Catalog "Pharmaceutical Stability Solutions"
8. Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery
9. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
10. Boston Scientific Announces Release of Next-Generation iLab(R) System Software
11. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
Breaking Biology News(10 mins):